The board of directors of Jenscare Scientific Co., Ltd. announced that the first clinical implantation of OmniSeal, a PFO occluder system developed by Ningbo Diochange Medical Technology Co., Ltd. (Zhu Bo Di Chuang Yi Liao Ke Ji You Xian Gong Si) ("Diochange Medical"), a wholly-owned subsidiary of the Company, has recently been successfully completed. OmniSeal has a number of advantages from its innovative design. Its unique fully punctureable design enables secondary intervention in the left heart system.

OmniSeal can adapt to different anatomical structures and shapes of patent foramen ovale, which reduces post-operation complications such as arrhythmias and atrial fibrillation. While ensuring effective occlusion, it also reduces residual shunt and the risk of blood clots. The successful completion of the first clinical implantation of OmniSeal has proven the design advantages of OmniSeal and marked a new stage of the Company's products for patent foramen ovale diseases.

OmniSeal is also the third innovative product of Diochange Medical entering clinical trial following its left atrial appendage occluder and interatrial shunt. The Company will continue to develop innovative products and implement a more holistic plan of commercialization for structural heart diseases so as to provide a complete solution for the majority of patients with structural heart diseases.